Imatinib mesylate-induced hyperpigmentation of the nose and palate

Annals of Dermatology

Volumn 26, Issue 4, 2014, Pages 532-533

  Song, Hyo Sang ^a   Kang, Hee Young ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928476571     PISSN: 10139087     EISSN: 20053894     Source Type: Journal    
DOI: 10.5021/ad.2014.26.4.532     Document Type: Letter

References (5)

1. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-206.
2. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-2487.
3. Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 2009;23:82-83.
4. Resende RG, Teixeira RG, Vasconcelos Fde O, Silva ME, Abreu MH, Gomez RS. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg 2012;40:e140-e143.
5. Cario-André M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol 2006;155:493-494.